Objective. The relationship between survival and early changes in the serum level of the CA-125 antigen in patients with advanced ovarian cancer remains poorly defined. Methods. To explore this issue, the serum CA-125 values from 101 patients with advanced ovarian cancer who participated in a Southwest Oncology Group trial (SWOG 8412), which compared the systemic delivery of cisplatin/cyclophosphamide vs. carboplatin/cyclophosphamide (both delivered every 28 days for 6 cycles) in suboptimal residual stage III and IV ovarian cancer, were evaluated. All patients in this analysis had CA-125 values available for at least 8 weeks following initiation of chemotherapy. Cox proportional hazards regression was used in multivariate analysis to determine the prognostic significance of the CA-125 concentration. Results. While pretreatment CA-125 values did not correlate with survival, the concentration of this tumor marker 8 weeks after initiation of therapy was a powerful independent prognostic factor. The median survivals for patients (n = 51) with a CA-125 < 35 U/ml, vs. patients (n = 50) with a CA-125 > 35 U/ml, at this time point, were 26 months and 15 months, respectively (P = 0.0001). Further, women with serum CA-125 values < 50% of their pretreatment concentration at 8 weeks experienced a median survival of 21 months, compared to only 10 months for individuals with tumor marker levels > 50% of their baseline value (P = 0.0003). Conclusion. Reduction in the serum CA-125 concentration over the initial two cycles of platinum-based chemotherapy is a powerful independent predictor of survival for patients with suboptimal stage III or IV ovarian cancer. Patients without significant declines in CA-125 after two cycles of platinum-based chemotherapy have a particularly poor prognosis. (c) 2006 Elsevier Inc. All rights reserved.

Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer / Markman, M; Federico, Massimo; Liu, Py; Hannigan, E; Alberts, D.. - In: GYNECOLOGIC ONCOLOGY. - ISSN 0090-8258. - STAMPA. - 103 (1):(2006), pp. 195-198. [10.1016/j.ygyno.2006.02.024]

Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer

FEDERICO, Massimo;
2006

Abstract

Objective. The relationship between survival and early changes in the serum level of the CA-125 antigen in patients with advanced ovarian cancer remains poorly defined. Methods. To explore this issue, the serum CA-125 values from 101 patients with advanced ovarian cancer who participated in a Southwest Oncology Group trial (SWOG 8412), which compared the systemic delivery of cisplatin/cyclophosphamide vs. carboplatin/cyclophosphamide (both delivered every 28 days for 6 cycles) in suboptimal residual stage III and IV ovarian cancer, were evaluated. All patients in this analysis had CA-125 values available for at least 8 weeks following initiation of chemotherapy. Cox proportional hazards regression was used in multivariate analysis to determine the prognostic significance of the CA-125 concentration. Results. While pretreatment CA-125 values did not correlate with survival, the concentration of this tumor marker 8 weeks after initiation of therapy was a powerful independent prognostic factor. The median survivals for patients (n = 51) with a CA-125 < 35 U/ml, vs. patients (n = 50) with a CA-125 > 35 U/ml, at this time point, were 26 months and 15 months, respectively (P = 0.0001). Further, women with serum CA-125 values < 50% of their pretreatment concentration at 8 weeks experienced a median survival of 21 months, compared to only 10 months for individuals with tumor marker levels > 50% of their baseline value (P = 0.0003). Conclusion. Reduction in the serum CA-125 concentration over the initial two cycles of platinum-based chemotherapy is a powerful independent predictor of survival for patients with suboptimal stage III or IV ovarian cancer. Patients without significant declines in CA-125 after two cycles of platinum-based chemotherapy have a particularly poor prognosis. (c) 2006 Elsevier Inc. All rights reserved.
2006
103 (1)
195
198
Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer / Markman, M; Federico, Massimo; Liu, Py; Hannigan, E; Alberts, D.. - In: GYNECOLOGIC ONCOLOGY. - ISSN 0090-8258. - STAMPA. - 103 (1):(2006), pp. 195-198. [10.1016/j.ygyno.2006.02.024]
Markman, M; Federico, Massimo; Liu, Py; Hannigan, E; Alberts, D.
File in questo prodotto:
File Dimensione Formato  
Significance of early......pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 99.33 kB
Formato Adobe PDF
99.33 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/22965
Citazioni
  • ???jsp.display-item.citation.pmc??? 27
  • Scopus 74
  • ???jsp.display-item.citation.isi??? 64
social impact